Shire finally gets Baxalta to the deal-talks table

Shire CEO Flemming Ornskov

Shire ($SHPG) is reportedly one step closer to achieving its dream of nabbing Baxalta ($BXLT) to become a global rare-disease leader. The two companies are in takeover talks, Bloomberg reported Friday, with the Illinois pharma looking for a sweetened bid with a cash component. The way Shire sees it, a combined company could generate $20 billion in sales by 2020, with as many as 30 new drugs rolling out over the next 5 years, CEO Flemming Ornskov has said. More from FiercePharma

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.